A Phase II Trial of Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Axitinib (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Therapeutic Use
- 29 May 2024 Trial design discussed in an abstract published at 60th Annual Meeting of the American Society of Clinical Oncology
- 29 Feb 2024 Planned End Date changed from 31 Jul 2026 to 28 Feb 2029.
- 29 Feb 2024 Status changed from recruiting to active, no longer recruiting.